These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15002635)

  • 1. Evidence-based and value-based formulary guidelines.
    Neumann PJ
    Health Aff (Millwood); 2004; 23(1):124-34. PubMed ID: 15002635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report.
    Fry RN; Avey SG; Sullivan SD
    Value Health; 2003; 6(5):505-21. PubMed ID: 14627057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMCP Format dossier requests: manufacturer response and formulary implications for one large health plan.
    Spooner JJ; Gandhi PK; Connelly SB
    J Manag Care Pharm; 2007; 13(1):37-43. PubMed ID: 17269835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers.
    Nichol MB; Knight TK; Epstein J; Honda DH; Tretiak R
    J Manag Care Pharm; 2007 May; 13(4):360-71. PubMed ID: 17506602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The arrival of economic evidence in managed care formulary decisions: the unsolicited request process.
    Neumann PJ
    Med Care; 2005 Jul; 43(7 Suppl):27-32. PubMed ID: 16056006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weighing the evidence: trends in managed care formulary decision making.
    de Lissovoy G
    J Clin Psychiatry; 2003; 64 Suppl 17():29-32. PubMed ID: 14680425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The AMCP format for formulary submissions version 2.1.
    J Manag Care Pharm; 2005 Jun; 11(5 Suppl B):vi-xvi, 1-29, 1-4. PubMed ID: 19186890
    [No Abstract]   [Full Text] [Related]  

  • 8. United States pharmacopeia development of the Medicare model formulary guidelines.
    Bielory L;
    Am J Geriatr Cardiol; 2005; 14(6):301-7. PubMed ID: 16276127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Showing outcomes and proving value brings success.
    Fullerton DS; Atherly D; Sullivan SD
    Manag Care Interface; 2001 Jun; 14(6):63-5, 71. PubMed ID: 11432153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Academy of Managed Care Pharmacy Format: relevance, rigor, regulation, and realism.
    O'Brien BJ
    Value Health; 2003; 6(5):501-2. PubMed ID: 14627055
    [No Abstract]   [Full Text] [Related]  

  • 12. The case for a value-based formulary: striving for total lowest net cost.
    Weart W; Bauman GR
    Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of clinical and economic evidence in dossier formulary submissions.
    Colmenero F; Sullivan SD; Palmer JA; Brauer CA; Bungay K; Watkins J; Neumann PJ
    Am J Manag Care; 2007 Jul; 13(7):401-7. PubMed ID: 17620035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A call for fairness in formulary decisions.
    Levinson W; Laupacis A
    Arch Intern Med; 2006 Jan; 166(1):16-8. PubMed ID: 16401806
    [No Abstract]   [Full Text] [Related]  

  • 15. Evidence-based decision making: using submission guidelines to inform formulary approvals.
    Anis AH
    Am J Manag Care; 1999 Mar; 5(3):356-8. PubMed ID: 10351031
    [No Abstract]   [Full Text] [Related]  

  • 16. Health care decision-maker perceptions and trends in the utilization of preapproval information for formulary decision-making.
    Brisibe T; Hikmat Z; Hydery T; Gorey C; Boswell K
    J Manag Care Spec Pharm; 2024 May; 30(5):475-479. PubMed ID: 38701027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validating pharmaceutical product claims: questions a formulary committee should ask.
    Schommer JC; Carlson AM; Rhee TG
    J Med Econ; 2015; 18(12):1000-6. PubMed ID: 26548326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of pharmacoeconomics to formulary decision making in managed care organizations.
    Suh DC; Okpara IR; Agnese WB; Toscani M
    Am J Manag Care; 2002 Feb; 8(2):161-9. PubMed ID: 11858228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulary decision-making considerations: COX-2 inhibitors.
    Shaya FT; Wong W; Shin JY; Martin L; Samant N
    Manag Care Interface; 2004 Nov; 17(11):29-36, 41. PubMed ID: 15573802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engaging community mental health stakeholders in pharmacy cost management.
    Baker JG
    Psychiatr Serv; 2001 May; 52(5):650-3. PubMed ID: 11331800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.